MedTrace Logo

Effects of Novel Sodium Bicarbonate Ingestion of Buffering Capacity

NCT03813329 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2019-01-23

No results posted yet for this study

Summary

One purpose of the present study was to evaluate the effect of elevating serum bicarbonate concentration more than had been achieved in previous studies without inducing potentially ergolytic GI distress. In order to do so, a modified SB ingestion protocol (ModSB) of 4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) was administered. It was hypothesized that ModSB would significantly elevate serum bicarbonate concentration to a greater extent than would an acute SB ingestion protocol (AcuteSB).

This study was also designed to corroborate the results of previous studies regarding the ergogenic effects of sodium bicarbonate ingestion. Most studies have administered sodium bicarbonate in solutions, which would make the participants aware of the substance ingested due to the distinctive flavor of SB, possibly inducing a placebo effect. All doses in the present study were administered in gelatin capsules to mask the flavor of the ingested substances, maintaining participant blindness to the procedure.

Blood samples were collected at baseline and following placebo (CaCO3), acute sodium bicarbonate ingestion, and modified sodium bicarbonate ingestion to determine the effects of the ingestion protocols on serum bicarbonate, sodium and lactate concentrations, as well as on serum pH and blood hematocrit. The study design was a randomized double-blind crossover.

Conditions

  • PERFORMANCE-ENHANCING EFFECT

Interventions

DIETARY_SUPPLEMENT

Modified Sodium Bicarbonate

4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of sodium bicarbonate

DIETARY_SUPPLEMENT

Acute Sodium Bicarbonate

3 progressively larger doses of calcium carbonate followed by one acute dose of sodium bicarbonate (300 mg/kg)

DIETARY_SUPPLEMENT

Calcium carbonate (placebo)

4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of calcium carbonate

Sponsors & Collaborators

  • California State University, Los Angeles

    collaborator OTHER

  • Long Island University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-05-01
Primary Completion
2004-10-31
Completion
2005-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03813329 on ClinicalTrials.gov